Tilebio secures £400k for AI pathology foundation models

Tilebio is developing AI pathology foundation models designed to learn a universal visual language of tissue from unlabelled medical images. The Glasgow-based company recently raised an estimated £400k, which brings its total funding for 2026 to £2m.

The technology enables automated interpretation for clinical diagnostics, biomarker discovery, and drug-target development by processing tumour tissue images into a proprietary language of cancer. By utilizing a large language model, the system is designed for pathology laboratories and pharmaceutical research organisations to detect cancer more accurately and earlier.

Incorporated in August 2025, the firm originated from research institutions including Cancer Research UK and the University of Glasgow. The business currently employs eight people and combines expertise in computer science, diagnostic histopathology, and molecular medicine. This latest capital injection follows an allotment of shares in June (filed in July).